Compare
Precigen, Inc. vs Janux Therapeutics, Inc. vs Zenas BioPharma, Inc. vs International Stem Cell Corp
| Latest fiscal year | Precigen, Inc. PGEN | Janux Therapeutics, Inc. JANX | Zenas BioPharma, Inc. ZBIO | International Stem Cell Corp ISCO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $9.68M | $10.00M | $10.00M | $9.10M |
| Revenue growth (YoY) | +146.7% | -5.6% | +100.0% | +0.2% |
| Gross margin | n/a | n/a | n/a | 55.7% (computed) |
| Operating margin | n/m | n/m | n/m | -2.9% |
| Net margin | n/m | n/m | n/m | -4.6% |
| Net income | -$250.64M | -$113.62M | -$377.74M | -$418.0K |
| EPS (Diluted) | -$1.37 | -$1.83 | -$8.44 | -$0.05 |
| Operating cash flow | -$87.83M | -$82.23M | -$172.33M | $8.0K |
| Free cash flow | -$89.83M | -$83.28M | -$172.35M | -$35.0K |
| Cash & equivalents | $30.23M | $52.33M | $110.64M | n/a |
| Total assets | $155.50M | $1.00B | $383.64M | $4.82M |
| Total liabilities | $134.59M | $44.74M | $141.50M | $4.58M |
| Shareholders' equity | $20.91M | $956.82M | $242.14M | -$4.06M |
| Return on year-end equity | n/m | -11.9% | -156.0% | n/a |
| Shares outstanding | 353.91M | 60.38M | 54.49M | 8.00M |
Revenue, most recent five fiscal years
| Fiscal year | Precigen, Inc. | Janux Therapeutics, Inc. | Zenas BioPharma, Inc. | International Stem Cell Corp |
|---|---|---|---|---|
| Latest | $9.68M Ended 2025-12-31 | $10.00M Ended 2025-12-31 | $10.00M Ended 2025-12-31 | $9.10M Ended 2025-12-31 |
| 1 year earlier | $3.92M Ended 2024-12-31 | $10.59M Ended 2024-12-31 | $5.00M Ended 2024-12-31 | $9.09M Ended 2024-12-31 |
| 2 years earlier | $6.22M Ended 2023-12-31 | $8.08M Ended 2023-12-31 | $50.00M Ended 2023-12-31 | $7.79M Ended 2023-12-31 |
| 3 years earlier | $26.91M Ended 2022-12-31 | $8.61M Ended 2022-12-31 | n/a | $8.18M Ended 2022-12-31 |
| 4 years earlier | $14.27M Ended 2021-12-31 | $3.64M Ended 2021-12-31 | n/a | $7.18M Ended 2021-12-31 |